Cardiovascular Disease (CVD)

MR. David likewise takes atorvastatin (Lipitor); 10 mg every day, for hypercholesterolemia (hoisted LDL cholesterol, low HDL cholesterol, and raised triglycerides). He has endured this medicine and holds fast to the day by day plan. Amid the previous 6 months, he has likewise taken chromium picolinate,

Current guidelines state that ezetimibe,is considered the best alternative for LDL reduction and tolerability in statin-intolerant patients and considered an adjuvant in this trial. The primary end point was percentage change from baseline to week 12 in LDL cholesterol. Other end points included measures of safety and tolerability of different doses of AMG145 and AMG145 plus ezetimibe. Other objectives included assessment of the safety and tolerability of 3 different doses of AMG145 and AMG145 plus ezetimibe compared with placebo plus ezetimibe. One hundred sixty patients were randomized into 5 groups, to take AMG 145 as monotherapy once a month at 280mg, 320mg and 420mg, to take AMG 145 420mg once a month with ezetimibe 10mg daily or placebo once a month with ezetimibe 10mg daily. At week 12 the AMG 145 groups had a percent change of blood levels of LDL from baseline from -40.8 % to -50.7 % dose ascending monotherapy and -63.0% with combination with ezetimibe versus -14.8% with combination of placebo and ezetimibe. Reduction in total cholesterol percentwise was from -29.8 % to -37.7 % dose ascending monotherapy and -43.3% with combination with ezetimibe versus -10.7% with combination of placebo and ezetimibe. The overall incidence of all adverse effects was similar among patients receiving

statins reduce the blood cholesterol level and decrease atherosclerosis build up in the coronary arteries.

Because heart disease and stroke is having such a profound effect on the United States population, “Increase overall cardiovascular health in the U.S. population” is one of HealthyPeople.gov (2014) main goal for

The patient does have a history of hyperlipidemia in the past. He, at one point, had been on a statin, which he thinks was simvastatin. He took it for several years and then moved, and essentially just stopped taking it. His lipids, after stopping the simvastatin, were last done in November of 2013 showing a total cholesterol 301, triglycerides 320, HDL 37, LDL 200. He then presented as a new patient here late last year. He had lipids done earlier in the spring showing an LDL of 174. He requested a trial of lifestyle, but unfortunately did not see improvement. His most recent lipids were just reviewed with him here. There were done on September 9th, showing total cholesterol 285,

Soran, H., Dent, R., & Durrington, P. (2017). Evidence-based goals in LDL-C reduction. Clinical Research in Cardiology, 106(4), 237–248. http://doi.org.starkstate.idm.oclc.org/10.1007/s00392-016-1069-7

     In today’s society, people are gaining medical knowledge at quite a fast pace. Treatments, cures, and vaccines for various diseases and disorders are being developed constantly, and yet, coronary disease remains the number one killer in the world.

According to an article by CNN from November of 2013 on the guideline chances "for many years, the goal was to get the 'bad' cholesterol levels -- or LDL levels -- below 100,’ Nissen said. ‘Those targets have been completely eliminated in the new guidelines, and the threshold for treatment has been eliminated’. ‘The focus for years has been on getting the LDL low,’ said Dr. Neil Stone, committee chairman. ‘By changing the way doctors evaluate a patient for statin therapy, Nissen said these new guidelines will effectively double the number of Americans eligible for statin therapy, bringing the total to about 72 million.” (“Statins are drugs that can lower your cholesterol.

Cardiovascular diseases (CVD), which include CHD, cerebrovascular disease, and peripheral vascular disease (PVD), is the leading cause of mortality in populations, particularly in the diabetic one. DM and PAD are both CAD equivalents ("coronary equivalents"). PAD is more common among those aged 50 years and older, with approximately 1 in 20 Americans in this age group affected [1].

Many studies were conducted on coronary artery disease (CAD) because it is the leading cause of mortality and premature disability so studies investigated those at risk of coronary atherosclerosis aiming to provide early treatment (Kolovou et al., 2005), (Akhabue et al., 2014).

A higher level of fats in the body puts the patient at higher risk for Cardiovascular diseases(CAD). The patient's' family has a history of CAD. Her mom and one of her sister have CAD (Lewis et al., 2014, pp. 733-734). The patient states that she has been taking her meds for cholesterol atorvastatin regularly. Her lipase level was 8272 on 11/11/16 and 2829 on 11/12/16 U/L 1069 on 11/13/16 (Ref range 73-393 U/L). Her HDL cholesterol level was 21 ( ref range>49 mg/dl), LDL Cholesterol level 148 ( ref range: <130 mg/dL). Patient statin drug was on hold because it is contradicted on the patient with an elevated level of ALT 80, 61(Ref range 0-50 U/L) and AST 61 on 11/12/16 and 64 on 11/13/16 (ref range 0-45 U/L). The uncontrolled level of could be the cause of concern for stroke or acute myocardial

Increased cholesterol levels, particularly low-density lipoprotein cholesterol (LDL-C), is one of the most potent CV risk factors. Epidemiological data show a continuous log-linear relationship between serum cholesterol levels and risk of CHD (Grundy et al. 2004). There are inconsistent reports of increased cholesterol levels in PD patients (Hayward et al. 1989; Tancer et al. 1990; Bajwa et al. 1992; Agargun et al. 1996; Shiori et al. 2000; Peter et al.

The number of U.S. deaths due to cardiovascular disease has drastically increased over the past century.

Probably the most ironic things of all is that means again in 1985 researchers learned a fail proof method to scale down ldl cholesterol with out the usage of any pharmaceutical medications. Actually, statins most effective appeared on the scene a brief even as later, and as is to be anticipated, they became the principal form of healing for top cholesterol. The common therapy i'm relating to is none instead of ascorbic acid.

Cardiovascular disease remains the leading cause of death, outranking cancer in the United States, according to the data from CDC National Center for Health Statistics. The American College of Cardiology/American Heart Association (ACC/AHA) periodically publishes guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. However, the 2013 ACC/AHA Guideline has still not gained multinational acceptance among providers (Stone, 2014). Pharmaceutical treatment versus lifestyle modification has been a controversy among the scientific community (Sinatra, 2014). Provider adherence to the 2013 ACC/AHA Cholesterol Guideline in order to achieve universal standard of care remains a challenge. The recent guideline represents a major shift from prior cholesterol management, as it`s primary focus is on the role of cholesterol treatment in atherosclerotic cardiovascular disease (ASCVD) risk reduction versus a comprehensive approach to lipid management (Finkel, 2015).